1. Home
  2. BRLT vs SKYE Comparison

BRLT vs SKYE Comparison

Compare BRLT & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brilliant Earth Group Inc.

BRLT

Brilliant Earth Group Inc.

HOLD

Current Price

$1.15

Market Cap

22.5M

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$0.73

Market Cap

24.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRLT
SKYE
Founded
2005
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.5M
24.2M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
BRLT
SKYE
Price
$1.15
$0.73
Analyst Decision
Hold
Strong Buy
Analyst Count
4
3
Target Price
$1.70
$15.00
AVG Volume (30 Days)
62.0K
190.3K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$437,483,000.00
N/A
Revenue This Year
$6.72
N/A
Revenue Next Year
$4.95
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.63
N/A
52 Week Low
$1.12
$0.57
52 Week High
$3.10
$5.75

Technical Indicators

Market Signals
Indicator
BRLT
SKYE
Relative Strength Index (RSI) 37.10 41.17
Support Level N/A $0.71
Resistance Level $1.64 $0.83
Average True Range (ATR) 0.10 0.08
MACD -0.03 -0.02
Stochastic Oscillator 18.75 3.29

Price Performance

Historical Comparison
BRLT
SKYE

About BRLT Brilliant Earth Group Inc.

Brilliant Earth Group Inc is an digitally native omnichannel jewelry company selling The company's products include rings, necklaces, earrings, and bracelets. Its collection of premium-quality diamond engagement and wedding rings, gemstone rings, and fine jewelry is conceptualized by in-house design studio. The company operates in one operating and reporting segment, the retail sale of diamonds, gemstones and jewelry.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: